MGC Pharmaceuticals said a patent had been granted, protecting its unique system used to deliver a cannabis-derived drug being developed to combat hard-to-treat forms of epilepsy, according to Proactive Investors.
The Slovenian Intellectual Property Office has not provided sign-off for CannEpil, which uses a self-nano emulsifying technology to carry the company’s high CBD, low THC medicinal compound.
CannEpil is one of four products approved for use in the Republic of Ireland, and prescribed to 300-400 people both in the Republic and in Australia.